LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis GBX 16.66 0.00 (0.00%) (As of 11/8/2022) Add Compare Share Share Stock Analysis Stock Analysis About 4D pharma Stock (LON:DDDD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 4D pharma alerts:Sign Up Key Stats Today's Range 16.66▼ 16.6650-Day Range 16.66▼ 16.6652-Week Range 16.66▼ 16.66Volume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address DDDD Stock News Headlines4D Molecular Therapeutics’ Positive Q3 and Strategic AdvancesNovember 16, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)November 14, 2024 | markets.businessinsider.comFree ebook reveals our #1 chart pattern for 2020, 2021, 2022, 2023 and 2024. It's time to get smart… We think many good traders get caught up in the wrong stocks and ultimately burn up their trading accounts, which is why we want to share something special with you… You see, our top technical trader just published a new e-book sharing his #1 stock pattern for the last 4 years… It’s the same pattern that’s helped him grow his model portfolio by an average of 85% per year since 2020, and he’s currently giving away digital copies for free. Inside, he’ll walk you through his #1 pattern, and show you why it forms. As you’ll see, it’s all thanks to the algorithmic anomaly caused by Wall Street’s trading algorithms… It's the main reason, this pattern paid out more than 72% of the time. November 29, 2024 | The TradingPub (Ad)Promising Clinical Data and Market Potential Justify Buy Rating for 4D Molecular TherapeuticsSeptember 20, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)September 19, 2024 | markets.businessinsider.com4D Molecular Therapeutics (FDMT) Receives a Buy from RBC CapitalSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising PipelineAugust 13, 2024 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth ProspectsJuly 26, 2024 | markets.businessinsider.comSee More Headlines DDDD Stock Analysis - Frequently Asked Questions How have DDDD shares performed this year? 4D pharma's stock was trading at GBX 16.66 on January 1st, 2024. Since then, DDDD stock has increased by 0.0% and is now trading at GBX 16.66. View the best growth stocks for 2024 here. How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) issued its quarterly earnings data on Wednesday, September, 30th. The company reported ($14.06) EPS for the quarter. How do I buy shares of 4D pharma? Shares of DDDD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Omega Diagnostics Group (ODX), Tullow Oil (TLW), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC). Company Calendar Last Earnings9/30/2020Today11/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DDDD CUSIPN/A CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-31,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718,000.00 Price / Sales41.84 Cash FlowGBX 11.60 per share Price / Cash Flow1.44 Book ValueGBX 18 per share Price / Book0.93Miscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.04 million OptionableNot Optionable Beta2.63 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (LON:DDDD) was last updated on 11/29/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredWhy Buffett, Bezos & Congress Are Rushing Into This SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.